NVCT Chief Science & Business Officer bought 2,000 shares at $4.99 on 2024-11-19; stock down 53.9% from 52-week high of $11.00.
Poradosu Enrique, Chief Science & Business Officer of Nuvectis Pharma, purchased 2,000 shares at $4.99 on 2024-11-19, increasing his holdings to 1,506,319 shares. The purchase occurs as NVCT trades 53.9% below its 52-week high of $11.00 and has declined 34.1% over the prior 30 days. Notably, Poradosu's single prior transaction at NVCT—a buy on 2024-05-10—subsequently returned 90d +8.7%, demonstrating successful timing of his prior entry at this ticker. The company reported a negative full-year net income of $-4.2M and maintains a market cap of $98.0M. The current buy at depressed price levels, paired with his track record of well-timed accumulation at this ticker, warrants attention to whether this signals renewed confidence amid the stock's sharp recent decline or reflects scheduled portfolio activity unrelated to valuation views.